Shehab Mohamed: Recognizing Isolated Thrombocytopenia as a Presentation of MDS
Shehab Mohamed, Hematologist at hammed Medical Corporation, shared a post on Linkedin about recent article he and his colleauges co-authored, published in Expert Review of Anticancer Therapy, adding:
“Here we go !
Pleased to share our newly published review:
‘Myelodysplastic syndromes/neoplasms presenting with isolated thrombocytopenia: a poorly understood pathophysiology, difficult to diagnose, and challenging to treat entity’
Published in Expert Review of Anticancer Therapy.
In this review, we explore MDS presenting with isolated thrombocytopenia (MDS-IT)—an uncommon and often underrecognized phenotype that can closely mimic immune thrombocytopenia (ITP). We discuss its pathophysiology, diagnostic challenges, distinction from ITP and CCUS, the significance of isolated del(20q), and current therapeutic considerations.
I am grateful to all my co-authors for their valuable contributions and collaboration.
A special thank you to Amer Zeidan and Jan Philipp Bewersdorf from Yale School of Medicine for their supervision, mentorship, and invaluable guidance throughout this work and my colleague Mohammed Elmourtada Abdulgayoom Abdulrahman Al-Mashdali Rowan Mesilhy
To link to this article.
I hope this review contributes to greater recognition of this challenging MDS phenotype and helps stimulate further research in an area where important diagnostic and therapeutic uncertainties remain.”
Title: Myelodysplastic syndromes/neoplasms presenting with isolated thrombocytopenia: a poorly understood pathophysiology, difficult to diagnose, and challenging to treat entity
Authors: Shehab F. Mohamed, Mohammed Abdulgayoom, Abdulrahman F. Al-Mashdali, Rowan Mesilhy, Jan Philipp Bewersdorf, Amer M. Zeidan
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 30, 2026, 17:43Santagata Davide: Can Targeting Inflammation Help Prevent Thrombosis?
-
Oct 30, 2026, 17:38Patrick Ellsworth: Supporting Patients and Families Through Bleeding Disorders Awareness and Community Initiatives
-
Oct 30, 2026, 17:33Ed Shovelin: Comparative Hemostatic Performance of CRP-A and Equine Fibrillar Collagen
-
Oct 30, 2026, 16:52Tosin Ola: A New Era in Sickle Cell Disease Treatment and the Question of Access
-
Oct 30, 2026, 16:48Cedric Hermans: The Next Generation of FVIIIa-Mimetic Antibodies in Haemophilia A
-
Oct 30, 2026, 16:40Amrita Sarkar: Advancing the Diagnosis of Anti-PF4 Syndromes
-
Oct 30, 2026, 16:35James Garrard: Driving Innovation in Stroke Care Through Global Collaboration
-
Oct 30, 2026, 16:19Cesar de Almeida Neto: Hemo 2026 Roundtable Focuses on the Challenges of Patient Blood Management
-
Oct 30, 2026, 16:01Marilena Vrana: The Case for Retaining Immunoglobulins on the EU Critical Medicines List